Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry R Davis

Showing results (151-160 of 185) with videos related to

Pageof 19
Sort By:
Plos Medicine|March 21, 2018
Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant dataKunal N Karmali, Donald M Lloyd-Jones, Joep van der Leeuw, et al.
Clinical Nephrology|December 1, 2016
Association between chronic kidney disease and cancer mortality: A report from the ALLHATDhruti P Chen, Barry R Davis, Lara M Simpson, et al.
Archives of Internal Medicine|June 29, 2005
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Paul K Whelton, Joshua Barzilay, William C Cushman, et al.
American Heart Journal|December 1, 2012
Cardiovascular risk assessment: addition of CKD and race to the Framingham equationPaul E Drawz, Sarah Baraniuk, Barry R Davis, et al.
Annals of Internal Medicine|February 8, 2006
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rateMahboob Rahman, Sara Pressel, Barry R Davis, et al.
BMJ (Clinical Research Ed.)|March 25, 2025
Effects of intensive blood pressure treatment on orthostatic hypertension: individual level meta-analysisStephen P Juraschek, Jiun-Ruey Hu, Jennifer L Cluett, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 19, 2008
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)William C Cushman, Charles E Ford, Paula T Einhorn, et al.
The Lancet. Diabetes & Endocrinology|July 25, 2022
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysisMilad Nazarzadeh, Zeinab Bidel, Dexter Canoy, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 4, 2002
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)William C Cushman, Charles E Ford, Jeffrey A Cutler, et al.
Circulation. Cardiovascular Quality and Outcomes|March 8, 2012
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension StudyJoshua I Barzilay, Barry R Davis, Sara L Pressel, et al.
Pageof 19

Showing results (151-160 of 185) with videos related to

Sort By:
Pageof 19
Plos Medicine|March 21, 2018
Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant dataKunal N Karmali, Donald M Lloyd-Jones, Joep van der Leeuw, et al.
Clinical Nephrology|December 1, 2016
Association between chronic kidney disease and cancer mortality: A report from the ALLHATDhruti P Chen, Barry R Davis, Lara M Simpson, et al.
Archives of Internal Medicine|June 29, 2005
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Paul K Whelton, Joshua Barzilay, William C Cushman, et al.
American Heart Journal|December 1, 2012
Cardiovascular risk assessment: addition of CKD and race to the Framingham equationPaul E Drawz, Sarah Baraniuk, Barry R Davis, et al.
Annals of Internal Medicine|February 8, 2006
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rateMahboob Rahman, Sara Pressel, Barry R Davis, et al.
BMJ (Clinical Research Ed.)|March 25, 2025
Effects of intensive blood pressure treatment on orthostatic hypertension: individual level meta-analysisStephen P Juraschek, Jiun-Ruey Hu, Jennifer L Cluett, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 19, 2008
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)William C Cushman, Charles E Ford, Paula T Einhorn, et al.
The Lancet. Diabetes & Endocrinology|July 25, 2022
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysisMilad Nazarzadeh, Zeinab Bidel, Dexter Canoy, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 4, 2002
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)William C Cushman, Charles E Ford, Jeffrey A Cutler, et al.
Circulation. Cardiovascular Quality and Outcomes|March 8, 2012
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension StudyJoshua I Barzilay, Barry R Davis, Sara L Pressel, et al.
Pageof 19